🏛️ Verified NIH Record • Updated 2026-08-18
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy (NCT06848231)
A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Dasher Neuroscience Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Who can join: Review the eligibility criteria below.
Location: UCLA Health — Los Angeles, California
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- UCLA Health — Los Angeles, California
- Brigham and Women's Hospital — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Columbia University Irving medical center — New York, New York
- Vanderbilt University Medical Center — Nashville, Tennessee
- Baylor College of Medicine — Houston, Texas
- Juntendo University Hospital — Tokyo,
- National Taiwan University Hospital — Taipei,
- National Taiwan University Hospital Cancer Center — Taipei,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple System Atrophy
- Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
- A Study of Lu AF82422 in Participants With Multiple System Atrophy — Fountain Valley, California
- GDNF Gene Therapy for Multiple System Atrophy — Irvine, California
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Scottsdale, Arizona
- Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic — Nashville, Tennessee
Explore by condition: All Multiple System Atrophy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.